Intracellular growth of an obligatory parasite Mycobacterium leprae. Host bacterial interactions

Talwar, G. P.; Krishnan, Anita; Jha, Pallavi; Mehra, V. L.

doi:10.1016/s0300-9084(74)80382-2

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…w vaccine (+MDT), no viable M . leprae were noticeable at 6 together with others stated above advocate the use of immunotherapy with this vaccine as an adjunct to chemotherapy for eventual eradication of leprosy.…”

Section: Therapeutic Leprosy Vaccine 241mentioning

confidence: 87%

An Immunotherapeutic Vaccine for Multibacillary Leprosy

1999

International Reviews of Immunology

View full text Add to dashboard Cite

On January 30, 1998, a vaccine for leprosy based on Mycobacterium w (the code word under which this species hitherto unspecified was investigated) was launched for public use for therapeutic purposes. The vaccine has completed phase III immunotherapeutic trials as an adjunct to chemotherapy in urban and rural leprosy control centres and has received the authorization from the Drugs Controller of India for industrial manufacture. It will be made available by M/s Cadila Pharmaceuticals, Ahmedabad. As an adjunct to chemotherapy, the vaccine expediates bacterial clearance and accelerates clinical regression of lesions. It shortens significantly the period for release from treatment (RFT) of patients. It is effective in inducing a fall of bacterial index (BI) in multibacillary patients who are either nonresponders or slow responders to the standard multidrug therapy and who have persistent BI over long periods. An additional benefit of immunization with this vaccine is the conversion of>60% of LL, 71% of BL and 100% of BB patients from lepromin negativity to lepromin positivity status. A significant number of vaccinated patients showed histopathological upgrading and eventually attainment of a state of nonspecific infiltration without dermal granulomas. The vaccine was well tolerated and the incidence of Type 2 reactions and their severity was less in combined immuno cum chemotherapy group than in the group receiving only chemotherapy. This review describes the nature of the vaccine and the way it was developed.

show abstract

Section: Therapeutic Leprosy Vaccine 241mentioning

confidence: 87%

An Immunotherapeutic Vaccine for Multibacillary Leprosy

1999

International Reviews of Immunology

View full text Add to dashboard Cite

show abstract

A destiny to fulfill

Gp¹

2005

J. Biosci.

View full text Add to dashboard Cite

Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties

Talwar¹,

Gupta²,

Mustafa

et al. 2017

BTT

Self Cite

View full text Add to dashboard Cite

This article reviews briefly the making of an immunoprophylactic-cum-immunotherapeutic vaccine against leprosy. The vaccine is based on cultivable, heat-killed atypical mycobacteria, whose gene sequence is now known. It has been named Mycobacterium indicus pranii. It has received the approval of the Drug Controller General of India and the US Food and Drug Administration. Besides leprosy, M. indicus pranii has found utility in the treatment of category II (“difficult to treat”) tuberculosis. It also heals ugly anogenital warts. It has preventive and therapeutic action against SP2/O myelomas. It is proving to be a potent adjuvant for enhancing antibody titers of a recombinant vaccine against human chorionic gonadotropin, with the potential of preventing pregnancy without derangement of ovulation and menstrual regularity in sexually active women.

show abstract

Intracellular growth of an obligatory parasite Mycobacterium leprae. Host bacterial interactions

Cited by 4 publications

References 8 publications

An Immunotherapeutic Vaccine for Multibacillary Leprosy

An Immunotherapeutic Vaccine for Multibacillary Leprosy

A destiny to fulfill

Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties

Contact Info

Product

Resources

About